Novo Nordisk Warns of 2026 Sales Dip as U.S. Pricing Pressures Mount; Shares Plunge
Novo Nordisk shares fell sharply after forecasting a potential sales decline for 2026, citing lower realized prices in the critical U.S. market and intensifying competition, despite robust growth in its international operations.